Health Care
Commentary
California could lead the way on bipartisan prescription drug reform
California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
Commentary
Record Obamacare Enrollment Embarrassment Masquerades as Victory
Just under 24 million Americans have purchased health coverage through the Affordable Care Act’s exchanges for 2025, marking yet another year of record-high enrollment. As in previous years, the Biden administration was quick to declare this surge in sign-ups a victory for patients. “Every American should have access to quality, ...
Commentary
The Dangers Hidden In CMS’ Drug Pricing Regulation
CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax ...
340B
Good Intentions Cannot Justify a Flawed Federal Health Policy
A government program may be the “nearest thing to eternal life we’ll ever see on this earth,” warned Ronald Reagan – even if it is flawed. Section 340B of the Public Health Services Act is a case in point. Enacted over 30 years ago, that law enables certain healthcare facilities, ...
Commentary
Canada’s Healthcare System Has No Place In The United States
When Justin Trudeau announced earlier this month that he would resign as prime minister of Canada, Donald Trump was ready with one of his go-to jokes. “Many people in Canada LOVE being the 51st State,” then President-elect Trump posted on social media, echoing his frequent assertion that the United States ...
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Commentary
Make Hospital Prices Transparent Again
In just a few days, President-elect Trump will reclaim the Oval Office. High on his list of priorities should be enforcing the hospital price transparency rules he announced during his first term. The rules, which took effect in 2021, require hospitals to publish prices for 300 common procedures — from ...
Commentary
Republicans can make Medicaid work again
The incoming Trump administration and Republican-controlled Congress are looking to rein in Medicaid, the health insurance entitlement that consumed a record 10% of the federal budget in 2023 despite delivering substandard care to its 79.4 million enrollees. Democrats are lining up to denounce the GOP’s plans, which they claim will ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
California could lead the way on bipartisan prescription drug reform
California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
Record Obamacare Enrollment Embarrassment Masquerades as Victory
Just under 24 million Americans have purchased health coverage through the Affordable Care Act’s exchanges for 2025, marking yet another year of record-high enrollment. As in previous years, the Biden administration was quick to declare this surge in sign-ups a victory for patients. “Every American should have access to quality, ...
The Dangers Hidden In CMS’ Drug Pricing Regulation
CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax ...
Good Intentions Cannot Justify a Flawed Federal Health Policy
A government program may be the “nearest thing to eternal life we’ll ever see on this earth,” warned Ronald Reagan – even if it is flawed. Section 340B of the Public Health Services Act is a case in point. Enacted over 30 years ago, that law enables certain healthcare facilities, ...
Canada’s Healthcare System Has No Place In The United States
When Justin Trudeau announced earlier this month that he would resign as prime minister of Canada, Donald Trump was ready with one of his go-to jokes. “Many people in Canada LOVE being the 51st State,” then President-elect Trump posted on social media, echoing his frequent assertion that the United States ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls
PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027. The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Make Hospital Prices Transparent Again
In just a few days, President-elect Trump will reclaim the Oval Office. High on his list of priorities should be enforcing the hospital price transparency rules he announced during his first term. The rules, which took effect in 2021, require hospitals to publish prices for 300 common procedures — from ...
Republicans can make Medicaid work again
The incoming Trump administration and Republican-controlled Congress are looking to rein in Medicaid, the health insurance entitlement that consumed a record 10% of the federal budget in 2023 despite delivering substandard care to its 79.4 million enrollees. Democrats are lining up to denounce the GOP’s plans, which they claim will ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
